A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Insufficient evidence exists to show efficacy of novel hypersensitivity pneumonitis therapies, indicating the need for clinical protocols.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Metastatic non-small cell lung cancer (NSCLC) occurs when the cancer spreads to other parts of the body, with stage 4 being the most advanced stage. Symptoms of metastatic NSCLC vary depending on ...

Despite advances in understanding lung cancer over the past two decades, it remains the number one cause of cancer-related deaths globally, claiming more than 1.7 million lives in 2018 1. This exceeds ...

Coughing is a way for your body to get rid of harmful things in your lungs. But coughing too much can be bad, too. If you’ve had a cough that’s gone on for what feels like forever, you might have a ...

Emphysema happens gradually as tobacco smoke or other pollutants damage the tiny air sacs in your lungs called alveoli. Normally, some 300 million alveoli help bring oxygen into your body and get rid ...